EUCTR2010-021041-42-IT
Active, not recruiting
Not Applicable
se of Calcimimetics vs oral Paricalcitol in Renal transplant Patients affected with Persistent Secondary Hyperparathyroidism. A pilot study - ND
AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA0 sitesOctober 8, 2010
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Renal transplant patients
- Sponsor
- AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Inclusion criteria in Lead\-in: Patient has received renal transplant more than 6 months before enrolment. Persistent secondary hyperparathyroidism after renal transplantation, intended as: Serum PTH higher than reference KDOQI range for the individual renal function. Serum Ca level:\>10,5 mg/dL and \< 12,5 mg/dL. GFR \>\= 15 mL/min 2\)Entry criteria at baseline (after 4 weeks cinacalcet lead\-in): Subjects should have a serum Ca level less than 10,2 mg/dL.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •\< 18 or \> 70 years of age. Participant to other studies in the last 30 days. Acute rejection. Acute intercurrent illness. Life expectancy \< 1 year for comorbid conditions. Any neoplasia. Use of Cinacalcet, Paricalcitol, biphosphonates or any form of vitamin D in the last 2 months (multivitamin supplements containing \<\= 400 IU of vitamin D are not restricted).Subject is currently receiving high doses (nonmaintenance therapy) of steroids ( \>\=10 mg/day of prednisone or equivalent)(except topical or inhaled glucocorticoids). Pregnant (confirmed by screening pregnancy test) or lactating females. Drugs intolerance. For any reason, subject is considered by the Investigator to be an unsuitable candidate to receive paricalcitol capsules and/or cinacalcet or is put at risk by study procedures.Subjects with serum Ca equal or greater than 10\.2 mg/dL after the 4\-week lead\-in phase will be excluded from the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Oral Paricalcitol versus Calcitriol in Peritoneal Dialysis Patients: effects on peritoneal transport and peritoneal defenceVerstoring peritoneale homeostase door peritoneaaldialysePeritoneal damage due to peritoneal dialysisNL-OMON37926Vrije Universiteit Medisch Centrum24
Active, not recruiting
Not Applicable
Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5. - PRIMO IIStage 5 Chronic Kidney Disease (CKD) in subjects receiving hemodialysis who have Left Ventricular Hypertrophy (LVH)MedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 14.1Level: PTClassification code 10049773Term: Left ventricular hypertrophySystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2007-005092-33-ITAbbott GmbH & Co. KG220
Active, not recruiting
Not Applicable
Paricalcitol capsules benefits in Renal failure Induced cardiac MOrbidity in subjects with Chronic Kidney Disease Stage 3B/4. - PRIMO IEUCTR2007-001689-34-ITAbbott GmbH & Co. KG220
Completed
Phase 2
Effect of oral calcitriol pulse therapy in comparison with oral daily calcitriol method in hemodiyalis paitientsSecondary hyperparathyroidism of renal origin.Secondary hyperparathyroidism of renal originGB90.4IRCT20111024007892N10Mashhad University of Medical Sciences20
Completed
Not Applicable
Cinacalcet and concurrent intravenous calcitriol for treatment of secondary hyperparathyroidism in dialysis patients compared with intravenous calcitriol alonesecondary hyperparathyroidismJPRN-UMIN0000034381.Division of Internal medicine, Seseragi hospital 2.Department of Medicine & Biological Science Gunma University Graduate School of Medicine100